Primary
-
ArQule announces tivantinib meets primary endpoint
ArQule announces tivantinib meets primary endpoint, significantly extending time to progression in Phase 2 trial in second-line hepatocellular carcinoma.
Primary | 13 March 2012
-
Bayer’s Xarelto (Rivaroxaban) meets primary efficacy endpoint, shows significant reduction in mortality in major study
Bayer HealthCare announced that the combination of oral Xarelto (Rivaroxaban) twice daily with standard antiplatelet therapy significantly reduced the composite primary efficacy endpoint of cardiovascular death, myocardial infarction and stroke in patients with acute coronary syndrome (ACS) compared to those receiving standard antiplatelet therapy alone.
Primary | 17 November 2011
-
Phase 3 trial of Regorafenib in metastatic colorectal cancer meets primary endpoint of improving overall survival
Bayer HealthCare announced positive results from its Phase 3 trial evaluating its investigational compound regorafenib (BAY 73-4506) for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.
Primary | 31 October 2011
-
Roche’s investigational treatment for asthma meets primary endpoint in phase 2 study
Lebrikizumab has potential to be the first personalized treatment for asthma.
Primary | 04 August 2011
-
Phase 3 trial of Novartis drug Afinitor met primary endpoint
Novartis announced phase 3 trial results that showed more than one-third of patients taking Afinitor (everolimus) tablets experienced a 50 percent or greater reduction in the size of their subependymal giant cell astrocytomas (SEGAs), non-cancerous b…
Primary | 08 July 2011
-
Merck’s investigational ophthalmic medication meets primary endpoint
Merck's investigational prostaglandin analogue ophthalmic medication tafluprost has met the primary endpoint in a phase 3 study. Data showed that patients with open-angle glaucoma or ocular hypertension, who were dosed once-daily with tafluprost, exp…
Primary | 02 May 2011
-
Second Lucentis phase 3 study meets primary endpoint
Genentech, a member of the Roche Group, announced today that the second of two phase 3 trials evaluating Lucentis (ranibizumab injection) in patients with diabetic macular edema (DME) met its primary endpoint. The primary endpoint of the study, known…
Primary | 25 March 2011
-
Phase 3 study of investigational compound Ipilimumab achieves primary endpoint
Bristol-Myers Squibb company announced that a clinical trial--known as study 024--of its investigational compound ipilimumab has met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma. Study 0…
Primary | 22 March 2011
-
Teplizumab did not meet primary efficacy endpoint
The Protege Data Monitoring Committee (DMC), composed of independent experts in the fields of diabetes and biostatistics, has completed a planned analysis of one-year safety and efficacy data of Macrogenics and Eli Lilly ’s Protege phase 3 clinical…
Primary | 13 January 2011
-
VEGF Trap-Eye achieves primary endpoint
Bayer and Regeneron ’s two parallel phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two month…
Primary | 04 January 2011
